← Leaderboards
Zhi Sheng
Virginia Polytechnic Inst And St Univ
$969,552
Attributed
$1,183,443
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $240.8K · FY2018–25$250K$187.5K$125K$62.5K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,183,443 · 3
By mechanism
R21$1,183,443 · 3
Top collaborators
- Deborah F Kelly2 shared
Others in their field
Other Emerging Leaders on “Proteins”
- John Damon Chodera · Sloan-Kettering Inst Can Research$50,971,767
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$40,723,314
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Research focus
ProteinsPhosphotransferasesFutureTumorRecurrenceGrowthCellsCatalytic DomainSuccessInnovationPten GeneResolutionComplexInsightPeptidesImageLaboratoriesBindingMutantImmunodeficient MouseChemotherapyKinase InhibitorMutationIn Vitro
Grant awards (6)
Overcoming therapy resistance in melanoma$176,809
R21 · FY2025 · CA · contact PI
Overcoming therapy resistance in melanoma$214,505
R21 · FY2024 · CA · contact PI
Cryo-EM analysis of PI3K signaling complexes in glioblastoma$186,978
R21 · FY2021 · CA · contact PI
Cryo-EM analysis of PI3K signaling complexes in glioblastoma$240,804
R21 · FY2020 · CA · contact PI
Selectively Targeting a PI3K subunit to overcome temozolomide resistance and treat recurrent glioblastoma$162,004
R21 · FY2019 · CA · contact PI
Selectively Targeting a PI3K subunit to overcome temozolomide resistance and treat recurrent glioblastoma$202,343
R21 · FY2018 · CA · contact PI